Sign in or create an account to add this stock to your watchlist.
About Auspex Pharmaceuticals (NASDAQ:ASPX)
Auspex Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people with movement disorders and other rare diseases, including orphan diseases. Its pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington's disease, an orphan disease, tardive dyskinesia and Tourette syndrome in the pediatric population, which is an orphan disease, as well as other orphan indications. Its lead product candidate is SD-809, which is a small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its other programs include SD-560, SD-1077 and SD-254.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:ASPX
CUSIPN/A
WebN/A
Phone+1-858-5582400
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-61.66%
Return on Assets-50.55%
Miscellaneous
EmployeesN/A
Outstanding Shares31,820,000
Auspex Pharmaceuticals (NASDAQ:ASPX) Frequently Asked Questions
What is Auspex Pharmaceuticals' stock symbol?
Auspex Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASPX."
How were Auspex Pharmaceuticals' earnings last quarter?
Auspex Pharmaceuticals Inc (NASDAQ:ASPX) posted its quarterly earnings data on Monday, March, 16th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.15. View Auspex Pharmaceuticals' Earnings History.
Has Auspex Pharmaceuticals been receiving favorable news coverage?
Media stories about ASPX stock have trended somewhat positive on Monday, according to Accern. Accern identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Auspex Pharmaceuticals earned a news sentiment score of 0.10 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 47.11 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Auspex Pharmaceuticals?
Shares of ASPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Auspex Pharmaceuticals' stock price today?
One share of ASPX stock can currently be purchased for approximately $100.96.
How big of a company is Auspex Pharmaceuticals?
Auspex Pharmaceuticals has a market capitalization of $3.21 billion.
How can I contact Auspex Pharmaceuticals?
Auspex Pharmaceuticals' mailing address is 3333 N Torrey Pines Ct Ste 400, LA JOLLA, CA 92037-1023, United States. The biopharmaceutical company can be reached via phone at +1-858-5582400.
MarketBeat Community Rating for Auspex Pharmaceuticals (ASPX)
MarketBeat's community ratings are surveys of what our community members think about Auspex Pharmaceuticals and other stocks. Vote "Outperform" if you believe ASPX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASPX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Auspex Pharmaceuticals (NASDAQ:ASPX) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
(Data available from 5/21/2016 forward)
Auspex Pharmaceuticals (NASDAQ:ASPX) Earnings History and Estimates Chart
Auspex Pharmaceuticals (NASDAQ ASPX) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/16/2015 | Q4 2014 | ($0.59) | ($0.74) | | | View | N/A |  |
| 11/10/2014 | Q3 2014 | ($0.45) | ($0.73) | | | View | N/A | |
| 8/7/2014 | Q2 2014 | ($0.40) | ($0.45) | | | View | N/A | |
| 5/13/2014 | Q114 | ($0.47) | ($0.52) | | | View | N/A | |
| 3/27/2014 | Q4 2013 | | ($0.05) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Auspex Pharmaceuticals (NASDAQ:ASPX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Auspex Pharmaceuticals (NASDAQ ASPX) Insider Trading and Institutional Ownership History
Auspex Pharmaceuticals (NASDAQ ASPX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/16/2015 | David A Stamler | Insider | Sell | 3,000 | $80.00 | $240,000.00 | | |
| 2/13/2015 | Ventures Vii Lp Cmea | Major Shareholder | Sell | 122,667 | $63.08 | $7,737,834.36 | | |
| 2/11/2015 | Ventures Vii Lp Cmea | Major Shareholder | Sell | 84,154 | $61.06 | $5,138,443.24 | | |
| 2/6/2015 | Ventures Vii Lp Cmea | Major Shareholder | Sell | 93,179 | $59.39 | $5,533,900.81 | | |
| 1/28/2015 | Alex Zisson | Director | Sell | 730,000 | $53.11 | $38,770,300.00 | | |
| 1/28/2015 | James E Flynn | Insider | Buy | 1,500,000 | $56.50 | $84,750,000.00 | | |
| 1/28/2015 | Panorama Capital, L.P. | Major Shareholder | Sell | 270,000 | $53.11 | $14,339,700.00 | | |
| 12/22/2014 | David A Stamler | Insider | Sell | 2,660 | $53.55 | $142,443.00 | | |
| 12/18/2014 | Ventures Vii Lp Cmea | Major Shareholder | Sell | 195,000 | $50.14 | $9,777,300.00 | | |
| 10/30/2014 | Ventures Vii Lp Cmea | Major Shareholder | Sell | 19,000 | $27.15 | $515,850.00 | | |
| 10/28/2014 | Ventures Vii Lp Cmea | Major Shareholder | Sell | 14,500 | $27.02 | $391,790.00 | | |
| 10/27/2014 | Ventures Vii Lp Cmea | Major Shareholder | Sell | 3,413 | $27.11 | $92,526.43 | | |
| 10/24/2014 | Ventures Vii Lp Cmea | Major Shareholder | Sell | 16,500 | $26.97 | $445,005.00 | | |
| 10/6/2014 | Ventures Vii Lp Cmea | Major Shareholder | Sell | 7,109 | $23.45 | $166,706.05 | | |
| 9/19/2014 | Gerald T Proehl | Director | Buy | 1,466 | $21.75 | $31,885.50 | | |
| 9/5/2014 | Ventures Vii Lp Cmea | Major Shareholder | Sell | 25,600 | $23.86 | $610,816.00 | | |
| 9/3/2014 | Ventures Vii Lp Cmea | Major Shareholder | Sell | 22,700 | $23.08 | $523,916.00 | | |
| 8/28/2014 | Ventures Vii Lp Cmea | Major Shareholder | Sell | 29,600 | $22.03 | $652,088.00 | | |
| 8/26/2014 | Ventures Vii Lp Cmea | Major Shareholder | Sell | 6,300 | $21.35 | $134,505.00 | | |
| 8/22/2014 | Ventures Vii Lp Cmea | Major Shareholder | Sell | 1,700 | $20.56 | $34,952.00 | | |
| 7/16/2014 | R Scott Greer | Director | Buy | 5,190 | $19.25 | $99,907.50 | | |
| 2/10/2014 | James E Flynn | Insider | Buy | 700,000 | $12.00 | $8,400,000.00 | | |
| 2/10/2014 | Panorama Capital, L.P. | Major Shareholder | Buy | 333,334 | $12.00 | $4,000,008.00 | | |
| 2/10/2014 | Pratik Shah | CEO | Buy | 8,333 | $12.00 | $99,996.00 | | |
| 2/10/2014 | Sepehr Sarshar | Director | Buy | 67,263 | $12.00 | $807,156.00 | | |
(Data available from 1/1/2013 forward)
Auspex Pharmaceuticals (NASDAQ ASPX) News Headlines
| Source: |
|
Auspex Pharmaceuticals (NASDAQ:ASPX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Auspex Pharmaceuticals (NASDAQ:ASPX) Income Statement, Balance Sheet and Cash Flow Statement
Auspex Pharmaceuticals (NASDAQ ASPX) Stock Chart for Monday, May, 21, 2018
Loading chart…
